Journal Article Summary
The article investigates how the prescribing patterns of new neuropsychiatric medications differ from established treatments and why this is important for understanding their safety and effectiveness. The study focuses on conditions such as diabetic peripheral neuropathy, Parkinson's disease psychosis, and epilepsy, which are commonly treated with both new and older medications. Understanding these prescribing trends is crucial because they can influence the outcomes of safety and effectiveness studies, potentially leading to biased results.
To conduct the research, the authors analyzed data from a national sample of commercially insured adults in the U.S. from 2005 to 2019. They compared new users of recently approved medications with those using established treatments for three specific conditions. The findings revealed that patients prescribed newer medications often had a history of prior treatments, indicating that these drugs are more frequently given to individuals with more complex cases or those who did not respond to older therapies. The study also noted that the differences in patient characteristics between those using new versus established drugs were most pronounced in the first year after the new medications became available.
The study has limitations, including potential biases in how patients are selected for treatment, which can affect the interpretation of safety and effectiveness. It highlights the importance of discussing these findings with healthcare professionals, especially when considering new treatments. Patients should be aware that newer medications may be prescribed for specific reasons, and understanding these factors can help them make informed decisions about their treatment options.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Abraham Danielle S., Nguyen Thanh Phuong Pham, Blank Leah J., Thibault Dylan, Gray Shelly L., Hennessy Sean, Leonard Charles E., Weintraub Daniel, et al.. Channeling of New Neuropsychiatric Drugs—Impact on Safety and Effectiveness Studies. Neurotherapeutics 2023. DOI: 10.1007/s13311-023-01344-w. PMID: 36864331. PMCID: PMC10121961.
Featured Pill Pals Product
Gabapentin 100 mg Capsules --- 30 Count --- Amneal Pharma --- Generic for Neurontin --- Total Dose = 1 Pill / Day --- 30 Day's Supply
Gabapentin 100 mg Capsules — 30 Count — Amneal Pharma — Generic for Neurontin — Total Dose = 1 Pill / Day — 30 Day’s Supply is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
